As Chief Executive Officer, Richard Francis is leading Teva to a new strategic path for growth by driving great science from the clinic to the patient to provide life-changing medications around the world. Mr. Francis assumes the role of Teva CEO with a compelling track record of growing businesses in the life sciences, biologics and generic drug sectors and is known for his entrepreneurial and pragmatic leadership style. He is passionate about people and culture and has a reputation for building talented teams that achieve remarkable results.

Mr. Francis brings over two and a half decades of experience to his position, including five years as the Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. Prior to that, Mr. Francis also spent 13 years as a senior executive at Biogen where he led the U.S. business through multiple successful commercial launches, including Tecfidera® to treat relapsing multiple sclerosis in 2013. Before joining Teva, Mr. Francis served as an operating Partner at Syncona and the Chief Executive Officer of Syncona’s portfolio companies - Forcefield Therapeutics, a pioneer of best-in-class therapeutics to protect heart function, and Purespring Therapeutics, an innovative gene therapy company. 

As an avid sports fan, Mr. Francis understands the importance of taking a team approach to drive impactful growth. He serves as a member of the board of directors of Mettler-Toledo International Inc. since 2016. He holds a Bachelor of Arts in Economics from The Manchester Metropolitan University.

Follow Richard on LinkedIn to see his latest updates.